A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/47 (2006.01) A61K 31/09 (2006.01) A61K 31/137 (2006.01) A61K 31/41 (2006.01) A61K 31/4515 (2006.01) A61K 31/454 (2006.01) A61K 31/4545 (2006.01) A61K 31/472 (2006.01) A61K 31/485 (2006.01) A61P 11/00 (2006.01) A61P 17/00 (2006.01)
Patent
CA 2315721
A pharmaceutical composition useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitus, allergy, asthma, allergic asthma and/or inflammation, in a mammalian organism in need of such treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from a) montelukast, b) 1-(((R)- (3-(2-(6,7- difluoro-2- quinolinyl)ethenyl) phenyl)-3-(2- (2-hydroxy- 2- propyl)phenyl) thio)methylcyclopropaneacetic acid; c) 1-(((1(R)-3 (3-(2-(2,3- dichlorothieno[3, 2-b]pyridin-5-yl) -(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl) phenyl)propyl) thio)methyl) cyclopropaneacetic acid; d) pranlukast or f) [2-[[2-(4-tert - butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixture with ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.
L'invention concerne une composition pharmaceutique utile dans le traitement de: l'éternuement, l'écoulement nasal provoquant des démangeaisons, la congestion nasale, l'énanthème conjonctival, la dilacération, les démangeaisons au niveau des oreilles ou du palais, la dyspnée, l'inflammation de la muqueuse bronchique, un indice de Thiffeneau faible (FEV1), la toux, l'éruption cutanée, l'affection cutanée purigineuse, les maux de tête, les douleurs continues et les algies associées à la rhinite allergique saisonnière, la rhinite allergique apériodique, le rhume banal, l'otite, la sinusite, l'allergie, l'asthme, l'asthme allergique et/ou l'inflammation, chez un organisme mammalien en ayant besoin. Ladite composition comprend: i) une dose efficace d'au moins un antagonise de leucotriène, choisi parmi a) montélukast; b) acide 1-(((R)- (3-(2-(6,7- difluoro-2- quinoléinyl) éthényl)phényl)-3- (2-(2-(2-hydroxy-2- propyl)phényl) thio)méthylcyclopropaneacétique; c) acide 1-(((1(R)-3 (3-(2-(2,3- dichlorothiéno [3,2-b]pyridin-5-yl) -(E)-éthényl)phényl) -3-(2-(1-hydroxy-1- méthyléthyl) phényl)propyl) thio)méthyl) cyclopropaneacétique; d) pranlukast; ou f) acide [2-[[2-(4-tert -butyl-2-thiazolyl) -5-benzofuranyl] oxyméthyl]phényl] acétique; ou un sel pharmaceutiquement acceptable de ceux-ci, en mélange avec ii) une dose efficace d'au moins un antihistamine, tel que descarboéthoxyloratidine, cétirizine, fexofénadine, ébastine, astémizole, norastémizole, épinastine, éflétirizine ou un sel pharmaceutiquement acceptable de ceux-ci.
Danzig Melvyn R.
Jensen Peder K.
Lorber Richard R.
Medeiros Paul T.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
LandOfFree
Composition for treating respiratory and skin diseases,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for treating respiratory and skin diseases,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treating respiratory and skin diseases,... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1563040